Search research articles
Contact Us
Filters
Showing results (81-90 of 153) with videos related to
Page
of 16
Sort By:
The Lancet. Respiratory Medicine
|
November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study
Hervé Léna, Laurent Greillier, Claire Cropet, et al.
The Oncologist
|
August 4, 2020
High Serum Vitamin B12 Levels Associated with C-Reactive Protein in Older Patients with Cancer
Anne-Laure Couderc, Eddy Puchades, Patrick Villani, et al.
Journal for Immunotherapy of Cancer
|
August 4, 2025
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study
Francois Ghiringhelli, Yaacov R Lawrence, Enriqueta Felip, et al.
Journal of Geriatric Oncology
|
July 31, 2021
Functional status in older patients with cancer
Anne-Laure Couderc, Pierre Suchon, Bérengère Saliba-Serre, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 25, 2018
Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey
Antonin Levy, Corinne Faivre-Finn, Baktiar Hasan, et al.
Oncotarget
|
May 20, 2017
Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients
Fabrice Barlesi, Diane-Charlotte Imbs, Pascale Tomasini, et al.
Journal of Cancer Research and Clinical Oncology
|
August 25, 2023
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
Hélène Doubre, Laurent Greillier, Grégoire Justeau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 2, 2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC
Jyoti Malhotra, Petros Nikolinakos, Ticiana Leal, et al.
The Lancet. Oncology
|
May 14, 2018
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial
Vanesa Gregorc, Rabab M Gaafar, Adolfo Favaretto, et al.
BMC Cancer
|
December 17, 2014
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
Isabelle Borget, Maurice Pérol, David Pérol, et al.
Page
of 16
Search research articles
Search
Showing results (81-90 of 153) with videos related to
Sort By:
Page
of 16
The Lancet. Respiratory Medicine
|
November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study
Hervé Léna, Laurent Greillier, Claire Cropet, et al.
The Oncologist
|
August 4, 2020
High Serum Vitamin B12 Levels Associated with C-Reactive Protein in Older Patients with Cancer
Anne-Laure Couderc, Eddy Puchades, Patrick Villani, et al.
Journal for Immunotherapy of Cancer
|
August 4, 2025
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study
Francois Ghiringhelli, Yaacov R Lawrence, Enriqueta Felip, et al.
Journal of Geriatric Oncology
|
July 31, 2021
Functional status in older patients with cancer
Anne-Laure Couderc, Pierre Suchon, Bérengère Saliba-Serre, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 25, 2018
Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey
Antonin Levy, Corinne Faivre-Finn, Baktiar Hasan, et al.
Oncotarget
|
May 20, 2017
Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients
Fabrice Barlesi, Diane-Charlotte Imbs, Pascale Tomasini, et al.
Journal of Cancer Research and Clinical Oncology
|
August 25, 2023
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
Hélène Doubre, Laurent Greillier, Grégoire Justeau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 2, 2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC
Jyoti Malhotra, Petros Nikolinakos, Ticiana Leal, et al.
The Lancet. Oncology
|
May 14, 2018
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial
Vanesa Gregorc, Rabab M Gaafar, Adolfo Favaretto, et al.
BMC Cancer
|
December 17, 2014
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
Isabelle Borget, Maurice Pérol, David Pérol, et al.
Page
of 16